Get started
Author

Ilaria Angeletti

Observed names: Angeletti I, I. Angeletti
OpenAlex ID: A5004322260
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study
2020 · Massimo Gentile, Fortunato Morabito, et al. · Leukemia · 23
Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study
2021 · Fortunato Morabito, Giovanni Tripepi, et al. · American Journal of Hematology · 14
PDF
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases
2021 · Fortunato Morabito, Giovanni Del Poeta, et al. · American Journal of Hematology · 13
PDF
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab
2020 · Massimo Gentile, Enrica Antonia Martino, et al. · Blood Cancer Journal · 12
PDF
Predictive value of the CLL ‐ IPI in CLL patients receiving chemo‐immunotherapy as first‐line treatment
2018 · Massimo Gentile, Tait D. Shanafelt, et al. · European Journal Of Haematology · 11
PDF
An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920)
2021 · Lydia Scarfo, Elisa Albi, et al. · Blood · 7
Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases
2020 · Fortunato Morabito, Giovanni Tripepi, et al. · European Journal Of Haematology · 7
PDF
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study
2025 · Ernesto Vigna, Enrica Antonia Martino, et al. · Hematological Oncology · 5
Management of infections for patient treated with ibrutinib in clinical practice
2024 · Claudia Baratè, Ilaria Scortechini, et al. · Frontiers in Oncology · 5
PDF
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort
2026 · Enrica Antonia Martino, Annalisa Pitino, et al. · Blood Advances · 4
PDF
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
2022 · Alberto Fresa, Francesco Autore, et al. · Blood Advances · 4
PDF
Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials
2021 · Fortunato Morabito, Giovanni Tripepi, et al. · American Journal of Hematology · 3
PDF
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study
2023 · Francesco Autore, Idanna Innocenti, et al. · Hematological Oncology · 2
A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial
2023 · Lydia Scarfo, Marta Coscia, et al. · Blood · 1
PDF
High-dose methotrexate, temozolomide, and intrathecal liposomal cytarabine (HD-MTX-TMZ-IT LC), without radiotherapy for central nervous system (CNS) lymphoma.
2011 · L. Falchi, M. Gunnellini, et al. · Journal of Clinical Oncology · 1
Response to Imatinib or Imatinib Containing Regimens of Secondary Clones in Chronic Myeloid Leukemia Patients with Additional Chromosomal Abnormalities.
2007 · Debora Luzi, Lorenzo Falchi, et al. · Blood · 1
Clinical Outcomes in Double‐Exposed Chronic Lymphocytic Leukemia Patients in Italy
2026 · Francesco Autore, Andrea Visentin, et al. · Hematological Oncology
Fitness in CLL
2026 · Claudia Baratè, Ilaria Scortechini, et al. · Cancers
PDF
A landscape of genetic heterogeneity in germline predisposition to familial chronic lymphocytic leukemia
2025 · Luca Laurenti, Eugenio Sangiorgi, et al. · Research Square
PDF
Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study
2025 · Alberto Fresa, Idanna Innocenti, et al. · Blood Advances
PDF
Familial Forms of Chronic Lymphocytic Leukemia Have a Worse Prognosis Than Sporadic Forms: an Italian Case-Control Study.
2025 · Fresa A, Innocenti I, et al. · Institutional Research Information System University of Turin (University of Turin)
PDF
Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study
2024 · Alberto Fresa, Idanna Innocenti, et al. · Blood
PDF
Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
2024 · Enrica Antonia Martino, Raffaella Pasquale, et al. · Blood
External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study
2019 · Massimo Gentile, Fortunato Morabito, et al. · Blood
High-dose Methotrexate, Temozolomide and Intrathecal Liposomal Cytarabine (hd-mtx-tmz-it Lc) Without Radiotherapy For Primary Or Secondary Central Nervous System (cns) Lymphoma
2011 · Lorenzo Falchi, Marco Gunnellini, et al.
Works count: 29
Citation count: 113
H-index: 7
I10-index: 5
Year
Topic
Type